Acute lung injury (ALI) is a life-threatening condition characterized by abnormal macrophage responses that lead to damage in the alveoli and other lung tissues, resulting in respiratory failure and increased mortality risk. Despite existing treatment approaches, current therapies remain ineffective in significantly alleviating the condition.
A research team led by Professor Kuang-Sheng Lee from the Department of Biomedical Science, MacKay Memorial Hospital, has discovered that mesenchymal stem cell (MSC)-derived exosomes exhibit powerful immunomodulatory properties, showing great potential in ALI treatment by reducing pulmonary inflammation and repairing damaged lung tissue.
miR-7704 Exosomes: A Breakthrough in ALI Treatment
Existing ALI treatments, such as corticosteroids and mechanical ventilation, provide temporary support but have limited efficacy and are often accompanied by side effects. Macrophage polarization plays a crucial role in ALI therapy, as M2 macrophages are capable of reducing pro-inflammatory cytokine production and facilitating tissue regeneration.
The research team identified a specific microRNA, miR-7704, that can effectively induce macrophages to adopt an anti-inflammatory M2 phenotype, thereby reducing pulmonary inflammation and promoting tissue repair. Animal studies demonstrated that nebulized administration of MSC-derived exosomes (MSC-EVs) efficiently delivered miR-7704 to the lungs of mice, leading to reduced lung inflammation, preserved lung structure, and improved respiratory function. The results showed that this approach not only mitigated lung injury but also significantly increased survival rates, highlighting its strong potential for clinical application.
Additionally, the team discovered that miR-7704 exerts its effects by inhibiting the MyD88/STAT1 signaling pathway, which plays a key role in acute inflammatory responses. Their findings suggest that miR-7704 effectively regulates immune responses, preventing further lung damage. Compared to conventional drug treatments, this exosome-based microRNA delivery system enhances drug delivery efficiency and precisely targets affected cells, further improving therapeutic outcomes. The success of this innovative technology marks a significant step toward a new era in ALI treatment.
Expert Insights: From Fundamental Research to Clinical Application
Professor Kuang-Sheng Lee emphasized that the successful development of this technology is the result of years of research on MSC-derived exosomes and a deep understanding of microRNA mechanisms. He pointed out that using exosomes as carriers to deliver miR-7704 represents one of the most promising innovations for ALI treatment. This approach not only reduces pulmonary inflammation but also promotes lung tissue repair and improves overall respiratory function.
The technology has already received a patent in Taiwan and is currently under patent application in the United States. The research team is also preparing to initiate clinical trials. Professor Lee expressed confidence that this breakthrough will provide a novel treatment option for ALI patients worldwide and contribute to advancing therapies for immune-related lung diseases.
Resource: 霧化注射間質幹細胞外泌體 減輕損傷促進肺修復
